PE20091755A1 - Composicion farmaceutica que comprende una sal de sulfato de hidrogeno de 6-(4-bromo-2-cloro-fenilamino)-7-fluoro-3-metil-3h-benzoimidazol-5-acido carboxilico (2-hidroxi-etoxi)-amida - Google Patents

Composicion farmaceutica que comprende una sal de sulfato de hidrogeno de 6-(4-bromo-2-cloro-fenilamino)-7-fluoro-3-metil-3h-benzoimidazol-5-acido carboxilico (2-hidroxi-etoxi)-amida

Info

Publication number
PE20091755A1
PE20091755A1 PE2009000461A PE2009000461A PE20091755A1 PE 20091755 A1 PE20091755 A1 PE 20091755A1 PE 2009000461 A PE2009000461 A PE 2009000461A PE 2009000461 A PE2009000461 A PE 2009000461A PE 20091755 A1 PE20091755 A1 PE 20091755A1
Authority
PE
Peru
Prior art keywords
benzoimidazol
phenylamine
bromo
fluoro
chloro
Prior art date
Application number
PE2009000461A
Other languages
English (en)
Inventor
Nicola Frances Bateman
Paul Richard Gellert
Kathryn Jane Hill
Original Assignee
Astrazeneca Ab
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40792932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091755(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Array Biopharma Inc filed Critical Astrazeneca Ab
Publication of PE20091755A1 publication Critical patent/PE20091755A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UNA SAL DE SULFATO DE HIDROGENO DE 6-(4-BROMO-2-CLORO-FENILAMINO)-7-FLUORO-3-METIL-3H-BENZOIMIDAZOL-5-ACIDO CARBOXILICO (2-HIDROXI-ETOXI)-AMIDA EN UNA CANTIDAD DE 5% A 30% POR PESO, DISPERSADA DENTRO DE UNA MATRIZ PORTADORA SELECCIONADA DE SUCCINATO DE D-ALFA-TOCOFERIL POLIETILENO GLICOL 1000, GLICERIDOS POLIGLICOLIZADOS, POLIETILENO GLICOLES (PEG) Y GRASAS DURAS. TAMBIEN ESTA REFERIDA A UN PROCESO DE PREPARACION
PE2009000461A 2008-03-28 2009-03-27 Composicion farmaceutica que comprende una sal de sulfato de hidrogeno de 6-(4-bromo-2-cloro-fenilamino)-7-fluoro-3-metil-3h-benzoimidazol-5-acido carboxilico (2-hidroxi-etoxi)-amida PE20091755A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4037208P 2008-03-28 2008-03-28

Publications (1)

Publication Number Publication Date
PE20091755A1 true PE20091755A1 (es) 2009-12-13

Family

ID=40792932

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000461A PE20091755A1 (es) 2008-03-28 2009-03-27 Composicion farmaceutica que comprende una sal de sulfato de hidrogeno de 6-(4-bromo-2-cloro-fenilamino)-7-fluoro-3-metil-3h-benzoimidazol-5-acido carboxilico (2-hidroxi-etoxi)-amida

Country Status (31)

Country Link
US (10) US20090246274A1 (es)
EP (1) EP2271321B1 (es)
JP (2) JP5547710B2 (es)
KR (1) KR101650958B1 (es)
CN (1) CN102046156B (es)
AR (2) AR071100A1 (es)
AU (1) AU2009229204B2 (es)
BR (1) BRPI0909267B8 (es)
CA (1) CA2718653C (es)
CL (1) CL2009000765A1 (es)
CO (1) CO6311068A2 (es)
CY (1) CY1113279T1 (es)
DK (1) DK2271321T3 (es)
EC (1) ECSP10010578A (es)
ES (1) ES2387942T3 (es)
HK (2) HK1149476A1 (es)
HR (1) HRP20120657T1 (es)
IL (1) IL208206A0 (es)
MX (1) MX2010010671A (es)
MY (1) MY157492A (es)
NZ (1) NZ588849A (es)
PE (1) PE20091755A1 (es)
PL (1) PL2271321T3 (es)
PT (1) PT2271321E (es)
RS (1) RS52409B (es)
SA (1) SA109300195B1 (es)
TW (1) TWI433840B (es)
UA (1) UA101654C2 (es)
UY (1) UY31737A (es)
WO (1) WO2009118562A1 (es)
ZA (1) ZA201006766B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI405756B (zh) * 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
SA109300195B1 (ar) 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان
CA2885969C (en) 2012-10-02 2021-04-06 Epitherapeutics Aps Substitued pyridine derivatives and compositions thereof useful as inhibitors of histone demethylases
US9650339B2 (en) 2013-02-27 2017-05-16 Gilead Sciences, Inc. Inhibitors of histone demethylases
EP3126345A1 (en) 2014-03-31 2017-02-08 Gilead Sciences, Inc. Inhibitors of histone demethylases
EA201790154A1 (ru) 2014-08-27 2017-08-31 Джилид Сайэнс, Инк. Соединения и способы для ингибирования гистоновых деметилаз

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022852A (en) 1993-10-22 2000-02-08 Hexal Ag Pharmaceutical composition containing cyclosporin A
NZ284068A (en) 1994-04-07 1998-06-26 Smithkline Beecham Plc Medicament comprising halofantrine free base
EP0825849A1 (en) 1995-05-19 1998-03-04 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
MY126358A (en) * 1996-03-22 2006-09-29 Glaxo Group Ltd Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
US5891469A (en) 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
ES2229473T3 (es) 1997-01-30 2005-04-16 Novartis Ag Composiciones farmaceuticas sin aceite que contienen ciclosporina a.
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6372251B2 (en) 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20050025791A1 (en) * 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
ES2407849T3 (es) 2002-03-13 2013-06-14 Array Biopharma, Inc. Derivados de bencimidazol alquilados N3 como inhibidores de MEK
AU2003267231A1 (en) 2002-09-20 2004-04-08 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US20040127551A1 (en) 2002-12-27 2004-07-01 Kai Zhang Taxane-based compositions and methods of use
TW200526221A (en) * 2003-09-02 2005-08-16 Imran Ahmed Sustained release dosage forms of ziprasidone
US20050096365A1 (en) 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
US20060003002A1 (en) 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
AR046773A1 (es) 2003-12-23 2005-12-21 Novartis Ag Formulaciones farmaceuticas de bisfosfonatos
CA2552925A1 (en) 2004-01-30 2005-08-18 Pfizer Italia S.R.L. Semisolid matrix pharmaceutical formulations
KR20050104152A (ko) * 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
WO2006138431A2 (en) 2005-06-16 2006-12-28 Eastman Chemical Company Methods and pharmaceutical formulations for increasing bioavailability
TWI405756B (zh) * 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
US9561178B2 (en) 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
BRPI0909185A2 (pt) 2008-03-20 2015-08-25 Virun Inc Derivado de vitamina e e seus usos
SA109300195B1 (ar) 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان

Also Published As

Publication number Publication date
BRPI0909267B1 (pt) 2020-07-07
US20170056375A1 (en) 2017-03-02
PT2271321E (pt) 2012-08-16
CA2718653C (en) 2016-02-09
TW200946511A (en) 2009-11-16
CL2009000765A1 (es) 2011-02-11
DK2271321T3 (da) 2012-08-27
AR071100A1 (es) 2010-05-26
JP2011515455A (ja) 2011-05-19
EP2271321B1 (en) 2012-06-13
KR101650958B1 (ko) 2016-08-24
TWI433840B (zh) 2014-04-11
CN102046156B (zh) 2014-12-17
CY1113279T1 (el) 2016-04-13
US20130195971A1 (en) 2013-08-01
US20090246274A1 (en) 2009-10-01
RU2491920C2 (ru) 2013-09-10
CO6311068A2 (es) 2011-08-22
AU2009229204B2 (en) 2012-05-24
WO2009118562A1 (en) 2009-10-01
MX2010010671A (es) 2011-06-20
PL2271321T3 (pl) 2013-03-29
US20160030574A1 (en) 2016-02-04
HRP20120657T1 (hr) 2012-09-30
CA2718653A1 (en) 2009-10-01
ECSP10010578A (es) 2010-11-30
HK1149476A1 (en) 2011-10-07
US11813246B2 (en) 2023-11-14
MY157492A (en) 2016-06-15
CN102046156A (zh) 2011-05-04
AR116001A2 (es) 2021-03-25
ZA201006766B (en) 2011-05-25
JP5547710B2 (ja) 2014-07-16
US20240041834A1 (en) 2024-02-08
US20190030004A1 (en) 2019-01-31
BRPI0909267B8 (pt) 2021-05-25
AU2009229204A1 (en) 2009-10-01
US20220087982A1 (en) 2022-03-24
HK1156844A1 (en) 2012-06-22
ES2387942T3 (es) 2012-10-04
US20200179344A1 (en) 2020-06-11
US20240041835A1 (en) 2024-02-08
RS52409B (en) 2013-02-28
EP2271321A1 (en) 2011-01-12
JP2014114320A (ja) 2014-06-26
IL208206A0 (en) 2010-12-30
NZ588849A (en) 2012-06-29
UY31737A (es) 2009-11-10
KR20110005246A (ko) 2011-01-17
BRPI0909267A2 (pt) 2017-05-30
SA109300195B1 (ar) 2013-04-20
RU2010143906A (ru) 2012-05-10
UA101654C2 (uk) 2013-04-25
US20120114750A1 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
PE20091755A1 (es) Composicion farmaceutica que comprende una sal de sulfato de hidrogeno de 6-(4-bromo-2-cloro-fenilamino)-7-fluoro-3-metil-3h-benzoimidazol-5-acido carboxilico (2-hidroxi-etoxi)-amida
PE20110419A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk
ES2548549T3 (es) Formulaciones de baterías de plomo y ácido que contienen nanotubos de carbono discretos
PE20130574A1 (es) Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
BR112012005029A2 (pt) ácidos sulfo-peroxicarboxílicos, seu preparo e métodos de uso como agentes alvejantes e antimicrobianos.
SV2011003855A (es) Heteroarilos sustituidos
EA031209B9 (ru) Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения
CO6361952A2 (es) Formulación de anticuerpo
CL2011002194A1 (es) Formulacion que comprende anticuerpo en un regulador de histidina-arginina ph 4.5 a 6.5; articulo de manufactura que comprende dicha formulacion; metodo para estabilizar un anticuerpo en una formulacion farmaceutica acuosa.
GEP20146198B (en) Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
EA200602077A1 (ru) Активируемые частицы, их получение и применение
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
CR8904A (es) Formulaciones estabilizadoras
PE20130590A1 (es) Derivados de tomaimicina como agentes citotoxicos
BR112014011055A2 (pt) novos derivados de [1,2,3]triazolo[4,5-d]pirimidina
DOP2012000281A (es) Composiciones farmaceuticas y metodos para su elaboracion
CO6390097A2 (es) Formulaciones para el cuidado oral que incrementa la cantidad de zinc soluble
UY29395A1 (es) Formulación de medicamentos conteniendo vardenafilo.
CL2008003016A1 (es) Composicion para tratamiento de lavanderia que comprende una base de tratamiento de lavanderia y desde 0,01 a 10% en peso de particulas de film laminar concavas coloreadas.
ECSP13012667A (es) Compuestos de triazolopiridina
CO6612226A2 (es) Tableta
UY29250A1 (es) Agentes citotóxicos que comprenden nuevos taxanos modificados en c-2.-
NI201100149A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia.
GT200900217A (es) Nuevos compuestos triciclicos, un proceso para su preparacion y las composiciones farmaceuticas que los contienen.
PE20090309A1 (es) Conjugado portador-caliqueamicina y un metodo de deteccion de caliqueamicina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal